Perspective Therapeutics (CATX) Gross Margin (2010 - 2023)

Perspective Therapeutics has disclosed Gross Margin across 14 years of filings, most recently posting 0.8% for Q4 2023.

• In Q4 2023, Gross Margin changed N/A year-over-year to 0.8%; the TTM figure through Dec 2023 stood at 100.0% (changed N/A YoY), while the FY2023 annual figure was 100.0%, changed N/A from the prior year.
• Gross Margin came in at 0.8% for Q4 2023 at Perspective Therapeutics, down from 33.78% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 59.24% in Q1 2020 to a low of 0.8% in Q4 2023.
• Average Gross Margin over 5 years is 41.63%, with a median of 45.69% recorded in 2019.
• Year-over-year, Gross Margin soared 1984 bps in 2019 and plunged 3183 bps in 2023.
• Over 5 years, Gross Margin stood at 50.36% in 2019, then slipped by 2 bps to 49.47% in 2020, then retreated by 12 bps to 43.32% in 2021, then decreased by 10 bps to 38.99% in 2022, then sank by 98 bps to 0.8% in 2023.
• Per Business Quant data, the three most recent Gross Margin figures were 0.8% in Q4 2023, 33.78% in Q3 2023, and 11.88% in Q2 2023.